Marketing-authorisation holder · Netherlands
Janssen Biologics B.V.
6 medicines in 3 countries, as authorisation holder and manufacturer.
Loading your page…
Loading your page…
Marketing-authorisation holder · Netherlands
6 medicines in 3 countries, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
6 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| SIMPONI 100 mg SOLUCION INYECTABLE EN PLUMA PRECARGADA100 mg · Solución inyectable en pluma precargada | Golimumab | Spain | Marketed | 2020 |
| SIMPONI 50 MG SOLUCION INYECTABLE EN PLUMA PRECARGADA50 mg · Solución inyectable en pluma precargada | Golimumab | Spain | Authorised | 2021 |
| SIMPONI 50mg SOLUCION INYECTABLE EN PLUMA PRECARGADA50 mg · Solución inyectable en jeringa precargada | Golimumab | Spain | Authorised | 2013 |
| Janssen COVID-19 Vaccine | Ad26 cov2s | Saudi Arabia | Authorised | |
| REMICADE 100 mg100mg · Pulb. pt. conc. pt. sol. perf. | Infliximab | Romania | unknown | |
| SIMPONI 50 mg50mg/0,5ml · Sol inj. | Golimumab | Romania | unknown |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 3 | 3 | 0 | CompaniesAll medicines |
| Romania | 2 | 0 | 2 | CompaniesAll medicines |
| Saudi Arabia | 1 | 1 | 0 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Ministerul Sănătății, Catalogul public naţional al preţurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licence: Serbian Open Data Licence (sodl)
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.